134 related articles for article (PubMed ID: 36654621)
1. Spontaneous Remission of Metastatic Castration-Resistant Prostate Cancer: Coley's Toxin Revisited?
Choe A; Mutsaers A; Rodrigues G; Chin J; Leung S; Winquist E
Cureus; 2022 Dec; 14(12):e32505. PubMed ID: 36654621
[TBL] [Abstract][Full Text] [Related]
2. Bioimmunoadjuvants for the treatment of neoplastic and infectious disease: Coley's legacy revisited.
Decker WK; Safdar A
Cytokine Growth Factor Rev; 2009 Aug; 20(4):271-81. PubMed ID: 19656718
[TBL] [Abstract][Full Text] [Related]
3. The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas.
McCarthy EF
Iowa Orthop J; 2006; 26():154-8. PubMed ID: 16789469
[TBL] [Abstract][Full Text] [Related]
4. The response of urological tumours to immunotherapy.
Gkialas I; Kalantzis A; Lykourinas M
J BUON; 2005; 10(3):329-36. PubMed ID: 17357186
[TBL] [Abstract][Full Text] [Related]
5. Talkin' Toxins: From Coley's to Modern Cancer Immunotherapy.
Carlson RD; Flickinger JC; Snook AE
Toxins (Basel); 2020 Apr; 12(4):. PubMed ID: 32283684
[TBL] [Abstract][Full Text] [Related]
6. Spontaneous regression: a hidden treasure buried in time.
Hoption Cann SA; van Netten JP; van Netten C; Glover DW
Med Hypotheses; 2002 Feb; 58(2):115-9. PubMed ID: 11812185
[TBL] [Abstract][Full Text] [Related]
7. A Systematic Review of the Emerging Role of Immune Checkpoint Inhibitors in Metastatic Castration-resistant Prostate Cancer: Will Combination Strategies Improve Efficacy?
Heidegger I; Necchi A; Pircher A; Tsaur I; Marra G; Kasivisvanathan V; Kretschmer A; Mathieu R; Ceci F; van den Bergh RCN; Thibault C; Tilki D; Valerio M; Surcel C; Gandaglia G;
Eur Urol Oncol; 2021 Oct; 4(5):745-754. PubMed ID: 33243663
[TBL] [Abstract][Full Text] [Related]
8. Development of Cancer Immunotherapies.
DeLucia DC; Lee JK
Cancer Treat Res; 2022; 183():1-48. PubMed ID: 35551655
[TBL] [Abstract][Full Text] [Related]
9. Challenges and Opportunities for Effective Cancer Immunotherapies.
Slaney CY; Kershaw MH
Cancers (Basel); 2020 Oct; 12(11):. PubMed ID: 33126513
[TBL] [Abstract][Full Text] [Related]
10. Identification of patients with metastatic castration-sensitive or metastatic castration-resistant prostate cancer using administrative health claims and laboratory data.
Freedland SJ; Ke X; Lafeuille MH; Romdhani H; Kinkead F; Lefebvre P; Petrilla A; Pulungan Z; Kim S; D'Andrea DM; Francis P; Ryan CJ
Curr Med Res Opin; 2021 Apr; 37(4):609-622. PubMed ID: 33476184
[TBL] [Abstract][Full Text] [Related]
11. Engineering Opportunities in Cancer Immunotherapy: After Decades of Missteps and Delays, a Growing Immune-Oncology Market and Improved Cancer Treatment Outcomes Open New Prospects for Biomedical Engineers and Data Scientists.
Zaharoff DA
IEEE Pulse; 2018; 9(4):8-11. PubMed ID: 30028678
[TBL] [Abstract][Full Text] [Related]
12. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K
Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
[TBL] [Abstract][Full Text] [Related]
13. Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology.
Nuhn P; De Bono JS; Fizazi K; Freedland SJ; Grilli M; Kantoff PW; Sonpavde G; Sternberg CN; Yegnasubramanian S; Antonarakis ES
Eur Urol; 2019 Jan; 75(1):88-99. PubMed ID: 29673712
[TBL] [Abstract][Full Text] [Related]
14. Bacterial Therapy of Cancer: Promises, Limitations, and Insights for Future Directions.
Kramer MG; Masner M; Ferreira FA; Hoffman RM
Front Microbiol; 2018; 9():16. PubMed ID: 29472896
[TBL] [Abstract][Full Text] [Related]
15. Pantoprazole Affecting Docetaxel Resistance Pathways via Autophagy (PANDORA): Phase II Trial of High Dose Pantoprazole (Autophagy Inhibitor) with Docetaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC).
Hansen AR; Tannock IF; Templeton A; Chen E; Evans A; Knox J; Prawira A; Sridhar SS; Tan S; Vera-Badillo F; Wang L; Wouters BG; Joshua AM
Oncologist; 2019 Sep; 24(9):1188-1194. PubMed ID: 30952818
[TBL] [Abstract][Full Text] [Related]
16. MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer.
Nickols NG; Nazarian R; Zhao SG; Tan V; Uzunangelov V; Xia Z; Baertsch R; Neeman E; Gao AC; Thomas GV; Howard L; De Hoedt AM; Stuart J; Goldstein T; Chi K; Gleave ME; Graff JN; Beer TM; Drake JM; Evans CP; Aggarwal R; Foye A; Feng FY; Small EJ; Aronson WJ; Freedland SJ; Witte ON; Huang J; Alumkal JJ; Reiter RE; Rettig MB
Prostate Cancer Prostatic Dis; 2019 Dec; 22(4):531-538. PubMed ID: 30804427
[TBL] [Abstract][Full Text] [Related]
17. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer.
Cornford P; Bellmunt J; Bolla M; Briers E; De Santis M; Gross T; Henry AM; Joniau S; Lam TB; Mason MD; van der Poel HG; van der Kwast TH; Rouvière O; Wiegel T; Mottet N
Eur Urol; 2017 Apr; 71(4):630-642. PubMed ID: 27591931
[TBL] [Abstract][Full Text] [Related]
18. Sequencing systemic therapies in metastatic castration-resistant prostate cancer.
Liu JJ; Zhang J
Cancer Control; 2013 Jul; 20(3):181-7. PubMed ID: 23811702
[TBL] [Abstract][Full Text] [Related]
19. Coley's toxin revisited: immunotherapy or plasminogen activator therapy of cancer?
Zacharski LR; Sukhatme VP
J Thromb Haemost; 2005 Mar; 3(3):424-7. PubMed ID: 15748226
[No Abstract] [Full Text] [Related]
20. Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients.
Azad AA; Eigl BJ; Murray RN; Kollmannsberger C; Chi KN
Eur Urol; 2015 Jan; 67(1):23-29. PubMed ID: 25018038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
